Hyperadrenergic POTS: Symptoms, Causes, & Treating the Subtype Most Doctors Miss Hyperadrenergic POTS affects an estimated 30 to 60% of all POTS patients, yet most are never told which subtype they have
IGF-DES Receptor Binding Specificity Competitive binding and receptor cross-linking experiments confirmed that both IGF-1 and des-(1-3)IGF-1 bind exclusively to the type 1 IGF receptor in L6 myoblasts, rat vascular smooth-muscle cells, and human lung fibroblasts with des-(1-3)IGF-1 demonstrating greater apparent potency in these assays, attributable to its low affinity for the competing 38 kDa IGFBP rather than differences in intrinsic receptor affinity
Coordinated ambushes struck security forces, killing at least 25 members of the National Guard, one prosecutorial agent, and one correctional officer
The supernatants were collected and stored at 80 C before further analysis
the per-component COA mass-spec data is the only direct status confirmation
Glutathione itself is synthesized intracellularly and is not absorbed systemically in significant amounts when taken orally, limiting the likelihood of competitive interactions